Screener
Denali Therapeutics Inc. DNLI Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $3.6M— | —— | —— | —— | $0— | ||
| $93K— | —— | —— | —— | $0— | ||
| $3.51M— | —— | —— | —— | $0— | ||
| 97.4%— | —— | —— | —— | —— | ||
| $97.02M-5.5% | $103.85M-10.7% | $97.91M-1.9% | $101.95M+3.8% | $102.7M+12.4% | ||
| $36.28M+12.4% | —— | —— | —— | $32.27M— | ||
| $134.15M-0.6% | —— | —— | —— | $134.96M— | ||
| -$130.54M+3.3% | -$137.36M+5.6% | -$137.37M-5.8% | -$137.43M-11.6% | -$134.96M-15.8% | ||
| -3,622.1%— | —— | —— | —— | —— | ||
| -$127.55M-2.8% | -$128.45M+3.4% | -$128.55M-12.0% | -$126.9M-18.4% | -$124.12M-25.3% | ||
| -3,539.2%— | —— | —— | —— | —— | ||
| -$0.68+5.6% | -$0.69+11.5% | -$0.73-7.4% | -$0.74-17.5% | -$0.72-22.0% | ||
| -$126.97M+3.7% | -$134.51M+6.1% | -$134.5M-5.1% | -$134.49M-10.8% | -$131.92M-15.1% | ||
| -3,523.1%— | —— | —— | —— | —— | ||
| -$130.54M+3.3% | -$137.36M+5.6% | -$137.37M-5.8% | -$137.43M-11.6% | -$134.96M-15.8% |
FAQ
- What is Denali Therapeutics Inc.'s revenue?
- Denali Therapeutics Inc. (DNLI) generated $3.6M in revenue over the trailing twelve months, up 184.4% year over year.
- Is Denali Therapeutics Inc. profitable?
- Denali Therapeutics Inc. is not currently profitable: it reported a net loss of $511.5M over the trailing twelve months, a -33121.9% net margin.
- What is Denali Therapeutics Inc.'s earnings per share?
- Denali Therapeutics Inc.'s diluted EPS over the trailing twelve months is $-2.84.
- Where does Denali Therapeutics Inc.'s income statement data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
